
CLPD (Chronic Lymphoproliferative Disorder) is a group of disorders characterized by the abnormal growth of lymphocytes, a type of white blood cell that helps the body fight infections. In some cases, CLPD may progress into leukemia, a cancer of the blood and bone marrow. Early detection and precise classification are essential for proper management and treatment.
The CLPD Advance uses flow cytometry to analyze multiple cell surface markers, including CD5, CD10, CD19, CD20, CD23, CD38, FM7, Kappa, Lambda, CD100, and others. Each marker provides information about the type and maturity of lymphocytes, helping doctors identify different subtypes of leukemia or lymphoproliferative disorders.
Doctors may recommend the CLPD Advance test for CLPD, Blood for patients who show symptoms such as unexplained fatigue, fever, weight loss, or frequent infections, or when there is a suspicion of leukemia or another blood disorder. It is also advised for patients undergoing treatment for leukemia to monitor progress, assess treatment effectiveness, and track disease progression. This test helps doctors identify specific types of white blood cells, diagnose different forms of leukemia, and guide personalized management decisions, making it essential for individuals whose medical history, symptoms, or blood test results indicate a possible lymphoproliferative disorder or leukemia.
For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.
The CLPD Advance measures multiple cell surface markers (antigens) on white blood cells to detect abnormal patterns in lymphocyte populations. It uses Flow Cytometry, a technique that evaluates the physical and chemical characteristics of cells in a fluid as they pass through lasers. This allows the test to determine the type of cells, their number, size, shape, and the presence of specific surface markers.
In the context of CLPD, Flow Cytometry helps identify whether the disorder involves B-cells, T-cells, or other lymphocyte types, and analyzes markers such as CD5, CD10, CD19, CD20, CD23, CD38, FM7, Kappa, Lambda, CD100, among others. These markers provide important information for classifying the type of lymphoproliferative disorder, assessing its aggressiveness, and differentiating between various forms of leukemia. By combining cell counts, physical characteristics, and marker expression, this test enables doctors to diagnose the disorder accurately, monitor treatment response, and guide personalized therapy decisions.
The CLPD Advance test is done:
- When you have symptoms such as unexplained fatigue, fever, weight loss, night sweats, or frequent infections.
- When there is suspicion of leukemia, lymphoma, or another blood disorder.
- When you are undergoing leukemia treatment to monitor response and disease progression.
- When your doctor wants to classify or confirm the type of lymphoproliferative disorder.
- To identify specific types of white blood cells, diagnose different forms of leukemia, classify the disorder, and guide treatment decisions.
- Provide your clinical history, previous test reports, and a valid prescription. Tata 1mg consolidated TRF to be filled.





















